• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

What do people know about clinical trials?

24.10.2018/in News /by Evgeniy Makarevich

In the JAMA Network Open published the results of a new survey on the importance of clinical research.
The survey showed that people are aware of the importance of clinical research (CT), but do not know how they are conducted.
The fact that clinical trials are important for the development of new drugs is considered by 85% of respondents (10,506 people); 90% of respondents (11,182 people) believe that CT are safe.
However, 5,578 out of 12,427 people (44.9%) reported that doctors rarely suggest participation in CT as a possible treatment method.

Ennik Anderson, the head of research and director of research services at the Information and Research Center, believes that one of the main reasons that impede the development of medicines is the difficulty in recruiting clinical trial participants. Increasing the level of knowledge about CT among “ordinary people” can be a good solution to this problem. After all, the ultimate goal of our work is to bring drugs to the market as soon as possible so that new effective treatment methods become available to patients.

The survey involved 12,427 respondents from 68 countries. Among the respondents were 2,200 people who participated in clinical trials. Survey participants were asked what they knew about the clinical study, how they got information about the research and what problems they encountered during their decision to participate in the CT.
Although most participants agreed that clinical research is important for the emergence of new drugs, more than half of them do not know where the research is being conducted. Respondents consider participation in clinical trials as burdensome for them. Among those who did participate in clinical studies, about half stated that this led to changes in their daily lives.

“We want to attract patients and medical staff in order to tell how the research protocol is being developed and to introduce them to the research procedures,” said Anderson. Previous studies have focused on the perspectives of researchers and physicians involved in the research, as well as on the difficulties in clinical trials. .
According to Susan Bartlett from Universtet McGill in Montreal, even today many drug studies do not pay enough attention to the information that patients report, such as fatigue or dyspeptic symptoms.
“In essence, we are conducting clinical trials to improve the lives of patients,” said Susan Bartlett to Reuters Health. “The possibility of conducting CT depends largely on the altruism of patients and their belief that the tests we carry out are safe and important for the development of science.”

Bartlett and colleagues conducted studies in the United States, Canada, and Australia on patients with arthritis. What doctors call “unpleasant side effects,” such as fatigue, diarrhea, and gastrointestinal pain, has been identified. They turned out to be common, permanent and “incapacitating” phenomena.
Even if the medicine helps with arthritis, it no longer matters if the patient is constantly feeling tired.
“Patient-oriented approaches in CT are in the early stages of development,” Bartlett added. “We assume that the cumulative effect of adverse reactions from drug intake has a significant impact on the quality of life of patients and reduces compliance with treatment.”

Methods are being developed to make patient-oriented clinical research. This includes identifying the risks and benefits of participation in CT, from the point of view of patients.
“Feel free to talk,” said Bartlett. “Tell us what we do well and where there is room for improvement.” We will all benefit from this.

Link: jamanetwork.com

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

3 + 5 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
120 years since the birth of Zinaida Ermolyeva The share of Indian pharmaceutical companies account for 39% of the total number...
Scroll to top